NCT05277051 2026-03-23First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid TumorsGlaxoSmithKlinePhase 1 Active not recruiting152 enrolled
NCT06405230 2026-02-03Evaluation of Programmed Death Ligand 1 (PDL1) Response to Treatment in Extracellular Vesicles (EVs), Patient-derived Organoid (PDOs)s and Immune-marker Positron Emission Tomography (PET) Scanning in Non-small Cell Lung Cancer (NSCLC)GlaxoSmithKlinePhase 1/2 Recruiting40 enrolled